Cancer’s Bitter Medicine

Alex Philippidis in today’s Genetic Engineering News provides an excellent review of the treatment costs for CML (chronic myeloid leukemia) which can exceed $100k/year.

However concern about the costs of cancer treatment has not yet hit the radar screen of major biotechnology analysts. Biopharmaceutical stocks are at an all time high due primarily to sales of cancer and anti-iflammatory drugs.

Pin It on Pinterest